Study:
S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III
Rationale:
Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is
not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing
neuropathy caused by chemotherapy.
Purpose:
This randomized phase III trial is studying acetyl-L-carnitine to see how well it
works compared with a placebo in preventing neuropathy in women with stage I, stage II, or
stage III breast cancer undergoing chemotherapy.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Breast Cancer
Chemotherapeutic Agent Toxicity
Fatigue
Neuropathy
Neurotoxicity |
Dietary Supplement: acetyl-L-carnitine hydrochloride
Other: placebo |
Phase 3 |
Verified by
Southwest Oncology Group
April, 2013
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00775645
Study Type: Interventional
Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Cleveland Clinic Beachwood Family Health and Surgery Center
Beachwood, Ohio 44122
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States
Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Laurence H. Baker, DO, FACOI., Principal Investigator